Affimed is a clinical-stage immuno-oncology company focused on discovering and developing targeted cancer immunotherapies. Co.'s main candidate, AFM13, is an innate cell engager (ICE®) designed for the treatment of certain CD30-positive malignancies, including for both Hodgkin lymphoma and certain non-Hodgkin lymphomas. Co.'s second candidate, AFM24, is designed to address limitations, such as toxicities or treatment resistance, associated with existing therapeutic anti-epidermal growth factor receptor monoclonal antibodies. Co.'s third wholly-owned ICE® molecule, AFM28, was developed from its ROCK® platform and is designed to bind to CD123, an established target in myeloid malignancies. The AFMD YTD return is shown above.
The YTD Return on the AFMD YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether AFMD YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the AFMD YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|